Biotech

Last summer researchers announced they had completed a rough draft of the human genome. Now the challenge is to sort out this new information so it can be put to use in battling disease. Proteins are the missing link between the genetic code and the disease process. Europe has promising companies in the emerging area of prote-omics, the study of proteins. Other European companies are first to market in developing new classes of drugs.
 

Actelion
Private company based in Allschwil, Switzerland
CEO:...

Want the full story?

Subscribe Now

Subscribe
Subscribe

Learn more about the benefits of being a TIME subscriber

If you are already a subscriber sign up — registration is free!